Results 11 to 20 of about 2,830 (142)

Farnesyl-diphosphate farnesyltransferase 1 promotes growth of colorectal cancer cells with dependence on tumor immune microenvironment

Di-san junyi daxue xuebao, 2021
Objective To investigate the effects of farnesyl-diphosphate farnesyltransferase 1 (FDFT1) on the growth of colorectal cancer (CRC) cell line MC-38 in vitro and in mouse models of colorectal peritoneal metastasis and xenograft tumor.
LUO Na, LUO Na, ZHANG Dapeng, MIAO Hongming, DAI Rongyang   +4 more
doaj   +2 more sources

Identification of FDFT1 as a potential biomarker associated with ferroptosis in ccRCC

Cancer Medicine, 2022
Renal cell carcinoma (RCC) seriously threatens people's lives and health. The identification of some precise biomarkers during the process of RCC progression and the pathophysiologic procedure is critical for improving the diagnosis and management of RCC.
Ruizhen Huang, Chiyu Zhang, Xing Wang, Xin Zou, Zhengjie Xiang, Zewei Wang, Bin Gui, Tao Lin, Honglin Hu   +8 more
doaj   +1 more source

Cholesterol mediated ferroptosis suppression reveals essential roles of Coenzyme Q and squalene

Communications Biology, 2023
Recent findings have shown that fatty acid metabolism is profoundly involved in ferroptosis. However, the role of cholesterol in this process remains incompletely understood.
Qi Sun, Diming Liu, Weiwei Cui, Huimin Cheng, Lixia Huang, Ruihao Zhang, Junlian Gu, Shuo Liu, Xiao Zhuang, Yi Lu, Bo Chu, Jian Li   +11 more
doaj   +1 more source

Prenylation Inhibition-Induced Cell Death in Melanoma: Reduced Sensitivity in BRAF Mutant/PTEN Wild-Type Melanoma Cells. [PDF]

, 2015
While targeted therapy brought a new era in the treatment of BRAF mutant melanoma, therapeutic options for non-BRAF mutant cases are still limited. In order to explore the antitumor activity of prenylation inhibition we investigated the response to ...
A Aparicio, A Carracedo, A Demunter, A Guenther, A Ladanyi, A Ladanyi, A Stachnik, AM Forsea, Andrea Réti, Anita Rózsás, B Chen, B Hegedus, B Hegedus, Balázs Döme, Balázs Hegedűs, BM Mueller, C Posch, C Riebeling, CA Rowell, CM Balch, CM Balch, CM Shipman, D Amin, DB Whyte, DR Budman, E Corey, E van Beek, EA Collisson, EC Lerner, Eszter Molnár, F Fabbri, F Meier, FG Haluska, H Davies, H Niessner, H Peng, H Tsao, H Tsao, HL Neville-Webbe, HM Weiss, István Kenessey, J Downward, J Liang, J Sonnemann, JA Curtin, JL Maldonado, Judit Dobos, József Tímár, József Tóvári, Keiran Smalley, KH Paraiso, KS Smalley, M Frattini, MH Nissan, ML Sos, MS Soengas, MV Lee, NM Appels, NO Carragher, P Tassone, PP Provenzano, R Blum, R Blum, R Blum, R Buzzeo, R Houben, R Kumar, R Srinivasan, S Derenne, SC Cremers, SG Senaratne, SM Sebti, SP Jagdev, T Garay, T Haapajarvi, T Iguchi, T Raz, T Yuen, Tamás Garay, V Lazar, V Mathieu, VA Nikolaou, Viktória László, VK Goel, W Berger, Walter Berger, Walter Klepetko, Y Egozi, Y Kloog, Y Nagata, Z Ji, Éva Juhász   +91 more
core   +8 more sources

Non-bisphosphonate inhibitors of isoprenoid biosynthesis identified via computer-aided drug design. [PDF]

, 2011
The relaxed complex scheme, a virtual-screening methodology that accounts for protein receptor flexibility, was used to identify a low-micromolar, non-bisphosphonate inhibitor of farnesyl diphosphate synthase.
Cao, Rong, Durrant, Jacob D, Gorfe, Alemayehu A, Li, Jikun, McCammon, J Andrew, Oldfield, Eric, Sankovsky, Anna, Zhu, Wei   +7 more
core   +2 more sources

Genetic engineering and molecular characterization of yeast strain expressing hybrid human-yeast squalene synthase as a tool for anti-cholesterol drug assessment [PDF]

, 2016
AIMS: The main objective of the study is molecular and biological characterization of the human-yeast hybrid squalene synthase (SQS), as a promising target for treatment of hypercholesterolaemia.
Burzynska, Beata, Danikiewicz, Witold, Gora, Monika, Kapur, S., Komaszylo, Joanna, Leszczynska, Agata, Maciejak, Agata, Plochocka, Danuta, Sojka, M., Swiezewska, Ewa, Tułacz, Dorota, Warchol, I., Wysocka-Kapcinska, Monika   +12 more
core   +1 more source

Raman spectroscopy biochemical characterisation of bladder cancer cisplatin resistance regulated by FDFT1: a review

Cellular & Molecular Biology Letters, 2022
Bladder cancer is the fourth most common malignancy in males. It can present across the whole continuum of severity, from mild through well-differentiated disease to extremely malignant tumours with poor survival rates.
M. Kanmalar, Siti Fairus Abdul Sani, Nur Izzahtul Nabilla B. Kamri, Nur Akmarina B. M. Said, Amirah Hajirah B. A. Jamil, S. Kuppusamy, K. S. Mun, D. A. Bradley   +7 more
doaj   +1 more source

Isoprenoids increase bovine endometrial stromal cell tolerance to the cholesterol-dependent cytolysin from Trueperella pyogenes† [PDF]

, 2018
Preventing postpartum uterine disease depends on the ability of endometrial cells to tolerate the presence of the bacteria that invade the uterus after parturition.
Amos, Ayres, Bergstrom, Bergstrom, Bicalho, Billington, Bloch, Bonnett, Bustin, Christian, Cronin, Forman, Fukuchi, Gan, Gareth D Healey, Goldstein, Goldstein, Gonzalez, Griffin, Gurcel, Hardie, Healy, Hiyoshi, Huffman, I Martin Sheldon, Jost, Kalaany, Karstrup, Keller, Lange, LeBlanc, LeBlanc, Liao, Maxfield, McCusker, Mihaylova, Moore, Morgan, Mosmann, Park, Peraro, Preta, Preta, Read, Repa, Schneider, Sharpe, Sheldon, Sheldon, Sholeem Griffin, Statt, Turner, Turner, Tweten, Vander Heiden, Wang, Wathes, Westermann, Zoncu, Zwald   +59 more
core   +1 more source

RETRACTED ARTICLE: Fasting inhibits aerobic glycolysis and proliferation in colorectal cancer via the Fdft1-mediated AKT/mTOR/HIF1α pathway suppression

Nature Communications, 2020
Evidence suggests that fasting exerts extensive antitumor effects in various cancers, including colorectal cancer (CRC). However, the mechanism behind this response is unclear.
Mei-lin Weng, Wan-kun Chen, Xiang-yuan Chen, Hong Lu, Zhi-rong Sun, Qi Yu, Peng-fei Sun, Ya-jun Xu, Min-min Zhu, Nan Jiang, Jin Zhang, Jian-ping Zhang, Yuan-lin Song, Duan Ma, Xiao-ping Zhang, Chang-hong Miao   +15 more
doaj   +1 more source

Inhibition of the mevalonate pathway augments the activity of pitavastatin against ovarian cancer cells [PDF]

, 2017
Only 40% of patients with advanced ovarian cancer survive more than 5 years. We have previously shown that pitavastatin induces regression of ovarian cancer xenografts in mice.
Abdullah, MI, Abed, MN, Richardson, A
core   +1 more source